The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

combio.biz

Founded Year

2000

Stage

Acquired | Acquired

Total Raised

$9.45M

About Combio

Developer of drugs based on genomic findings. The company focuses on the discovery and development of low molecular-weight drugs as well as peptide and peptidomimetic drugs. The company's drug discovery approach makes use of post genomic era opportunities for the design of improved drugs. The process is enhanced by the fact that there is a common feature to different classes of biological targets, so that each drug discovery effort benefits from the accumulated experience of previous programs that address similar targets.

Combio Headquarter Location

Vesterbrogade 188 / Frydendalsvej 32

Frederiksberg, 1800,

Denmark

45 70 222 365

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Combio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Combio is included in 1 Expert Collection, including Omics.

O

Omics

1,265 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Combio Patents

Combio has filed 1 patent.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Experimental cancer drugs
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/9/2018

5/10/2022

Monoclonal antibodies, Experimental cancer drugs, Clusters of differentiation, Tyrosine kinase receptors, Immune system

Grant

Application Date

4/9/2018

Grant Date

5/10/2022

Title

Related Topics

Monoclonal antibodies, Experimental cancer drugs, Clusters of differentiation, Tyrosine kinase receptors, Immune system

Status

Grant

Latest Combio News

Sihuan Pharma Acquires Beijing Combio, an Antibody/Bispecific Company

Jan 27, 2021

publication date: Jan 27, 2021 Sihuan Pharma will acquire Beijing Combio Pharma for an undisclosed price. An innovative biopharma, Combio is developing 12 preclinical molecules that it discovered using its two antibody platforms: Mab Edit (antibody editing) and Mebs-Ig (antibody editing for bispecific antibodies). Combio will become part of Sihuan's existing novel drug development company, Xuanzhu Biopharm. In August 2020, Xuanzhu raised $148 million in venture capital at a $700 million valuation.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.